PURPOSE: To improve risk-adapted therapy for localized childhood soft tissue sarcoma within an international multicenter setting. PATIENTS AND METHODS: Four hundred forty-one patients younger than 21 years with localized rhabdomyosarcoma and rhabdomyosarcoma-like tumors (ie, extraosseous tumors of the Ewing family, synovial sarcoma, and undifferentiated sarcoma) were eligible. Therapy was stratified according to postsurgical stage, histology, and tumor site. In unresectable tumors, treatment was further adapted depending on response to induction chemotherapy, TN classification, tumor size and second-look surgery. A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86. Hyperfractionated accelerated radiotherapy (HART) was recommended at doses of either 32 or 48 Gy. RESULTS: At a median follow-up of 8 years, 5-year event-free survival (EFS) and overall (OS) survival for the entire cohort was 63% +/- 4% and 73% +/- 4%, respectively (all survival rates in this abstract are calculated and displayed with +/-95% CI). EFS/OS rates by histology were 60% +/- 5%/72% +/- 5% in rhabdomyosarcoma, 62% +/- 10%/69% +/- 10% for Ewing tumors of soft tissues, 84% +/- 12%/90% +/- 10% for synovial sarcoma, and 67% +/- 38%/83% +/- 30% for undifferentiated sarcoma, respectively. Response to one cycle of the five-drug combination EVAIA was similar to that of the four-drug combination VAIA used in CWS-86. Two hundred twelve patients with rhabdomyosarcoma underwent radiation (EFS, 66% +/- 6%); 53 of those patients had a favorable risk profile and received 32 Gy of HART (EFS, 73% +/- 12%). TN classification, tumor site, tumor size, histology, and age were prognostic in univariate analysis. CONCLUSION: Improved risk stratification enabled decreased therapy intensity for selected patients without compromising survival. Intensified chemotherapy with EVAIA did not improve outcome of localized high-risk rhabdomyosarcoma.
PURPOSE: To improve risk-adapted therapy for localized childhood soft tissue sarcoma within an international multicenter setting. PATIENTS AND METHODS: Four hundred forty-one patients younger than 21 years with localized rhabdomyosarcoma and rhabdomyosarcoma-like tumors (ie, extraosseous tumors of the Ewing family, synovial sarcoma, and undifferentiated sarcoma) were eligible. Therapy was stratified according to postsurgical stage, histology, and tumor site. In unresectable tumors, treatment was further adapted depending on response to induction chemotherapy, TN classification, tumor size and second-look surgery. A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86. Hyperfractionated accelerated radiotherapy (HART) was recommended at doses of either 32 or 48 Gy. RESULTS: At a median follow-up of 8 years, 5-year event-free survival (EFS) and overall (OS) survival for the entire cohort was 63% +/- 4% and 73% +/- 4%, respectively (all survival rates in this abstract are calculated and displayed with +/-95% CI). EFS/OS rates by histology were 60% +/- 5%/72% +/- 5% in rhabdomyosarcoma, 62% +/- 10%/69% +/- 10% for Ewing tumors of soft tissues, 84% +/- 12%/90% +/- 10% for synovial sarcoma, and 67% +/- 38%/83% +/- 30% for undifferentiated sarcoma, respectively. Response to one cycle of the five-drug combination EVAIA was similar to that of the four-drug combination VAIA used in CWS-86. Two hundred twelve patients with rhabdomyosarcoma underwent radiation (EFS, 66% +/- 6%); 53 of those patients had a favorable risk profile and received 32 Gy of HART (EFS, 73% +/- 12%). TN classification, tumor site, tumor size, histology, and age were prognostic in univariate analysis. CONCLUSION: Improved risk stratification enabled decreased therapy intensity for selected patients without compromising survival. Intensified chemotherapy with EVAIA did not improve outcome of localized high-risk rhabdomyosarcoma.
Authors: Sophia Marie Häußler; Carmen Stromberger; Heidi Olze; Georg Seifert; Steffen Knopke; Arne Böttcher Journal: J Cancer Res Clin Oncol Date: 2017-11-16 Impact factor: 4.553
Authors: Monika Scheer; Tobias Dantonello; Peter Brossart; Dagmar Dilloo; Lothar Schweigerer; Simone Feuchtgruber; Monika Sparber-Sauer; Christian Vokuhl; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak; Thekla von Kalle Journal: Pediatr Radiol Date: 2018-01-24
Authors: J H M Merks; G L De Salvo; C Bergeron; G Bisogno; A De Paoli; A Ferrari; A Rey; O Oberlin; M C G Stevens; A Kelsey; J Michalski; D S Hawkins; J R Anderson Journal: Ann Oncol Date: 2014-01 Impact factor: 32.976
Authors: Maximilian Rudert; Cornelia Winkler; Boris Michael Holzapfel; Hans Rechl; Peter Kneschaurek; Reiner Gradinger; Michael Molls; Barbara Röper Journal: Strahlenther Onkol Date: 2010-03-26 Impact factor: 3.621
Authors: Martin Benesch; André O von Bueren; Tobias Dantonello; Katja von Hoff; Torsten Pietsch; Ivo Leuschner; Alexander Claviez; Uta Bierbach; Gabriele Kropshofer; Rudolf Korinthenberg; Norbert Graf; Meinolf Suttorp; Rolf Dieter Kortmann; Carsten Friedrich; Nicolas von der Weid; Peter Kaatsch; Thomas Klingebiel; Ewa Koscielniak; Stefan Rutkowski Journal: J Neurooncol Date: 2012-12-11 Impact factor: 4.130
Authors: Odile Oberlin; Annie Rey; Kenneth L B Brown; Gianni Bisogno; Ewa Koscielniak; Michael C G Stevens; Douglas S Hawkins; William H Meyer; Trang H La; Modesto Carli; James R Anderson Journal: Pediatr Blood Cancer Date: 2015-08-10 Impact factor: 3.167
Authors: Abby R Rosenberg; James R Anderson; Elizabeth Lyden; David A Rodeberg; Suzanne L Wolden; Simon C Kao; David M Parham; Carola Arndt; Douglas S Hawkins Journal: Eur J Cancer Date: 2013-12-18 Impact factor: 9.162